Full metadata record

DC Field Value Language
dc.contributor.authorLee, SH-
dc.contributor.authorNam, SY-
dc.contributor.authorChung, BC-
dc.date.accessioned2024-01-21T16:38:44Z-
dc.date.available2024-01-21T16:38:44Z-
dc.date.created2021-09-03-
dc.date.issued1998-10-
dc.identifier.issn0009-9120-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/142837-
dc.description.abstractObjective: The aim of this study was to investigate the possible effect of prolactin on the metabolism of androgens acid estrogens in patients with prolactinoma. To accomplish this, prolactin, urinary androgen, and estrogen metabolite levels were determined. In order to indirectly evaluate the possible involvement of enzymes, the concentration ratios of precursor metabolite to product metabolite were also compared with controls. Methods: Urine samples were obtained from 27 female patients with prolactinoma (macro, micro, and idiopathic) and from 31 age-matched normal female subjects. Urinary metabolites of 21 androgens and corticoids and 20 estrogens were analyzed by a gas chromatography-mass spectrometry system. Results: In patients with prolactinoma, urinary 17-ketosteroids, and all estrogen metabolite concentrations were elevated. The ratios of Delta(5)/Delta(4)-steroids and 5 beta/5 alpha-hydrogensteroids were higher in the patients with prolactinoma than in normal female controls. In addition, no significant differences between patients and controls were observed in the precursor metabolite to product metabolite ratios relating to estrogen metabolism. Conclusion: Our data suggests that enhanced PRL levels have a direct effect on urinary steroid secretion and metabolism, probably due to lowered activities of 5 alpha-reductase and 3 beta-hydroxysteroid dehydrogenase in the patients with prolactinoma. Copyright (C) 1998 The Canadian Society of Clinical Chemists.-
dc.languageEnglish-
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD-
dc.subjectGROWTH-HORMONE-
dc.subjectESTROGEN-
dc.subjectSECRETION-
dc.titleAltered profile of endogeneous steroids in the urine of patients with prolactinoma-
dc.typeArticle-
dc.identifier.doi10.1016/S0009-9120(98)00063-0-
dc.description.journalClass1-
dc.identifier.bibliographicCitationCLINICAL BIOCHEMISTRY, v.31, no.7, pp.529 - 535-
dc.citation.titleCLINICAL BIOCHEMISTRY-
dc.citation.volume31-
dc.citation.number7-
dc.citation.startPage529-
dc.citation.endPage535-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000076771400003-
dc.identifier.scopusid2-s2.0-0032176688-
dc.relation.journalWebOfScienceCategoryMedical Laboratory Technology-
dc.relation.journalResearchAreaMedical Laboratory Technology-
dc.type.docTypeArticle-
dc.subject.keywordPlusGROWTH-HORMONE-
dc.subject.keywordPlusESTROGEN-
dc.subject.keywordPlusSECRETION-
dc.subject.keywordAuthorprolactinoma-
dc.subject.keywordAuthorandrogen-
dc.subject.keywordAuthorestrogen-
dc.subject.keywordAuthorgas chromatography mass spectrometry-
Appears in Collections:
KIST Article > Others
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE